Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCGB vs BEAM in High-risk or R/R Lymphomas
NCT05466318Phase 3Recruiting
- Sponsor
- Sichuan University
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL) and Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sichuan University. Primary endpoint: Progression Free Survival at 2 years. Started Jul 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT05466318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466318.